Disclaimer: Selank is sold strictly for laboratory research purposes only. It is not approved for human consumption or medical use. This article discusses published scientific research and does not constitute medical advice or treatment recommendations.
Understanding Selank Peptide
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derivative of the naturally occurring tetrapeptide tuftsin, originally developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. The peptide sequence was engineered by extending tuftsin with a Pro-Gly-Pro tripeptide to enhance metabolic stability while maintaining the immunomodulatory properties of its parent molecule.
In research contexts, Selank has been investigated primarily for its potential anxiolytic (anxiety-reducing) properties and effects on cognitive performance. A comprehensive review by Vyunova et al. (2018) detailed the molecular aspects of Selank’s biological activity, demonstrating that the peptide acts as a positive allosteric modulator of GABAA receptors, offering a distinct pharmacological profile from traditional benzodiazepine anxiolytics (PMID: 30255741).
Important: Selank is intended for laboratory research use only and is not intended for human or animal consumption. All information presented here reflects published preclinical and clinical research findings.
Mechanism of Action
Research suggests Selank may influence brain function through multiple pathways:
GABAergic Gene Expression: Volkova et al. (2016) published a key study in Frontiers in Pharmacology demonstrating that Selank administration produced significant changes in the expression of 45 out of 84 genes involved in GABAergic neurotransmission within one hour of administration. The research established that Selank functions through allosteric modulation of the GABAergic system rather than direct receptor binding (PMID: 26924987).
Monoamine Neurotransmitter Modulation: Narkevich et al. (2008) conducted a comparative study examining Selank’s effects on monoamine content across brain structures in two mouse strains (BALB/C and C57Bl/6), measuring dopamine, norepinephrine, serotonin, and their metabolites. The study revealed strain-dependent effects on these neurotransmitter systems (PMID: 19093364).
BDNF Expression: Kolik et al. (2019) found that Selank protected against ethanol-induced memory impairment by regulating brain-derived neurotrophic factor (BDNF) content in the hippocampus and prefrontal cortex in rats, suggesting neuroprotective mechanisms linked to neurotrophic factor regulation (PMID: 31625062). Earlier work by Inozemtseva et al. (2008) had also confirmed that intranasal Selank administration regulates BDNF expression in the rat hippocampus in vivo (PMID: 18841804).
Immune System Interaction: Building on tuftsin’s immunomodulatory properties, Kolomin et al. (2011) demonstrated that Selank and its fragments significantly altered the expression of 35 genes encoding chemokines, cytokines, and their receptors in mouse spleen within 6-24 hours of a single dose (PMID: 21786679).
Research Findings on Anxiety
Multiple preclinical and clinical studies have examined Selank’s effects on anxiety-like behaviors. All findings discussed below are from laboratory and controlled research settings only; Selank is not approved for therapeutic use.
Zozulia et al. (2008) conducted a randomized clinical trial comparing Selank to medazepam (a benzodiazepine) in 62 patients with generalized anxiety disorder and neurasthenia. The study found comparable anxiolytic effects between the two compounds, but Selank additionally demonstrated antiasthenic and psychostimulant properties without the sedation or motor impairment typically associated with benzodiazepines (PMID: 18454096).
A 2017 study by Kasian et al. in Behavioural Neurology examined Selank in combination with diazepam under chronic mild stress conditions in rats. Individual Selank administration was the most effective at reducing elevated anxiety levels, while the Selank-diazepam combination proved most effective under unpredictable chronic mild stress conditions (PMID: 28280289).
Cognitive Performance Research
Beyond anxiolytic properties, research has investigated Selank’s potential cognitive effects:
Kolik et al. (2019) demonstrated that Selank protected against ethanol-induced memory impairment in rodent models, with effects linked to BDNF regulation in the hippocampus and prefrontal cortex. The study showed improved performance in spatial memory tasks in Selank-treated animals compared to ethanol-only controls (PMID: 31625062).
The peptide’s cognitive effects appear to involve multiple neurotransmitter systems. The strain-dependent monoamine modulation documented by Narkevich et al. suggests that Selank’s effects on attention and working memory may be mediated through dopaminergic and serotonergic pathways in the prefrontal cortex (PMID: 19093364).
Immunomodulatory Properties Under Stress
Yasenyavskaya et al. (2021) published an important study in Current Reviews in Clinical and Experimental Pharmacology examining Selank’s influence on cytokine levels under social stress conditions. The research demonstrated that Selank reduced concentrations of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α as well as TGF-β1, practically restoring them to control values. These findings suggest Selank may possess stress-protective properties through immunomodulatory pathways (PMID: 32621722).
Dosage in Research Studies
Published research protocols vary considerably:
Preclinical studies: Typically use doses ranging from 0.1-1.0 mg/kg body weight in rodent models
Human studies: Limited published data, but clinical trials have used intranasal administration at doses between 0.3-3.0 mg per day
Duration: Most studies examine acute effects or short-term administration (7-14 days)
Note: These are research protocols only. Selank is a research chemical not approved for human use outside of controlled research settings.
Safety Profile in Research
Available safety data comes primarily from preclinical studies and limited clinical investigations:
The clinical trial by Zozulia et al. (2008) noted that Selank was generally well tolerated, with the peptide’s lack of direct benzodiazepine receptor binding contributing to a different side effect profile than traditional anxiolytics—specifically, an absence of the sedation, amnesia, and dependence concerns associated with benzodiazepines (PMID: 18454096).
The Vyunova et al. (2018) review also emphasized that Selank’s mechanism as a positive allosteric modulator of GABAA receptors, rather than a direct agonist, may contribute to its favorable safety profile in research contexts (PMID: 30255741). However, comprehensive long-term safety data remains limited and further investigation is needed.
Current Research Directions
Ongoing investigations are examining:
Long-term safety and efficacy profiles in controlled research settings
Optimal dosing regimens and administration routes
Combination effects with other nootropic compounds, including synergistic effects with diazepam documented by Kasian et al.
Potential applications in neurodegenerative disease models through BDNF-mediated neuroprotection
Stress-protective immunomodulatory mechanisms and cytokine regulation
Gene expression profiling to better understand GABAergic and monoaminergic interactions
Related Research Peptides
Scientists investigating cognitive function and neuroprotection also study several related compounds:
Semax: Another Russian-developed peptide with reported nootropic properties, structurally related to ACTH
Cerebrolysin: A peptide mixture investigated for neuroprotective effects in stroke and dementia models
P21: A peptide derived from CNTF, studied for potential cognitive enhancement and neuroplasticity effects
Conclusion
Selank represents an interesting research tool for investigating anxiolytic mechanisms that differ from traditional GABAergic drugs. Current evidence from preclinical and limited clinical studies suggests potential effects on anxiety-like behaviors and cognitive function, mediated through multiple neurotransmitter systems and neurotrophic factors. The peptide’s unique position as a positive allosteric GABAA modulator with additional immunomodulatory properties makes it a compelling subject for continued laboratory investigation.
However, significant research gaps remain, particularly regarding long-term safety, optimal dosing protocols, and fully elucidating mechanisms of action. The peptide’s status as a research chemical means it lacks the comprehensive safety and efficacy data required for medical approval in most countries. All research with Selank should be conducted in accordance with applicable regulations and guidelines for research chemicals.
Future large-scale clinical trials with rigorous methodology will be essential to validate preliminary findings and establish whether Selank’s research promise translates to therapeutic applications.
Research References:
Vyunova TV, et al. “Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity.” Protein & Peptide Letters. 2018;25(10):914-923. PMID: 30255741
Volkova A, et al. “Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.” Frontiers in Pharmacology. 2016;7:31. PMID: 26924987
Kolik LG, et al. “Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats.” Bull Exp Biol Med. 2019;167(5):641-644. PMID: 31625062
Inozemtseva LS, et al. “Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo.” Dokl Biol Sci. 2008;421:241-3. PMID: 18841804
Zozulia AA, et al. “Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia.” Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454096
Kasian A, et al. “Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats.” Behavioural Neurology. 2017;2017:5091027. PMID: 28280289
Yasenyavskaya AL, et al. “The Influence of Selank on the Level of Cytokines Under the Conditions of Social Stress.” Curr Rev Clin Exp Pharmacol. 2021;16(2):162-167. PMID: 32621722
Kolomin TA, et al. “Changes in expression of the genes for chemokines, cytokines, and their receptors in response to selank and its fragments.” Genetika. 2011;47(5):711-4. PMID: 21786679
Narkevich VB, et al. “Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/C and C57Bl/6 mice: a comparative study.” Eksp Klin Farmakol. 2008;71(5):8-12. PMID: 19093364
All research chemicals sold by Oath Research are intended for laboratory research use only. Not for human or animal consumption. Researchers must comply with all applicable regulations regarding the use of research chemicals.
Curious about semax, nootropic peptide research? This article unpacks the science, mechanisms, and lab considerations behind the Russian-developed compound prized for its cognitive and neuroprotective promise.
Melanotan 2 (MT2) is a synthetic analog of alpha-melanocyte stimulating hormone that has gained attention in research settings for its effects on melanogenesis and melanocortin receptor pathways. While researchers explore its potential applications, understanding the complete side effect profile is essential for experimental safety protocols and informed study design. This comprehensive guide examines documented adverse …
Selank Peptide: Research on Anxiolytic Effects and Cognitive Function
Disclaimer: Selank is sold strictly for laboratory research purposes only. It is not approved for human consumption or medical use. This article discusses published scientific research and does not constitute medical advice or treatment recommendations.
Understanding Selank Peptide
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derivative of the naturally occurring tetrapeptide tuftsin, originally developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. The peptide sequence was engineered by extending tuftsin with a Pro-Gly-Pro tripeptide to enhance metabolic stability while maintaining the immunomodulatory properties of its parent molecule.
In research contexts, Selank has been investigated primarily for its potential anxiolytic (anxiety-reducing) properties and effects on cognitive performance. A comprehensive review by Vyunova et al. (2018) detailed the molecular aspects of Selank’s biological activity, demonstrating that the peptide acts as a positive allosteric modulator of GABAA receptors, offering a distinct pharmacological profile from traditional benzodiazepine anxiolytics (PMID: 30255741).
Important: Selank is intended for laboratory research use only and is not intended for human or animal consumption. All information presented here reflects published preclinical and clinical research findings.
Mechanism of Action
Research suggests Selank may influence brain function through multiple pathways:
Research Findings on Anxiety
Multiple preclinical and clinical studies have examined Selank’s effects on anxiety-like behaviors. All findings discussed below are from laboratory and controlled research settings only; Selank is not approved for therapeutic use.
Zozulia et al. (2008) conducted a randomized clinical trial comparing Selank to medazepam (a benzodiazepine) in 62 patients with generalized anxiety disorder and neurasthenia. The study found comparable anxiolytic effects between the two compounds, but Selank additionally demonstrated antiasthenic and psychostimulant properties without the sedation or motor impairment typically associated with benzodiazepines (PMID: 18454096).
A 2017 study by Kasian et al. in Behavioural Neurology examined Selank in combination with diazepam under chronic mild stress conditions in rats. Individual Selank administration was the most effective at reducing elevated anxiety levels, while the Selank-diazepam combination proved most effective under unpredictable chronic mild stress conditions (PMID: 28280289).
Cognitive Performance Research
Beyond anxiolytic properties, research has investigated Selank’s potential cognitive effects:
Kolik et al. (2019) demonstrated that Selank protected against ethanol-induced memory impairment in rodent models, with effects linked to BDNF regulation in the hippocampus and prefrontal cortex. The study showed improved performance in spatial memory tasks in Selank-treated animals compared to ethanol-only controls (PMID: 31625062).
The peptide’s cognitive effects appear to involve multiple neurotransmitter systems. The strain-dependent monoamine modulation documented by Narkevich et al. suggests that Selank’s effects on attention and working memory may be mediated through dopaminergic and serotonergic pathways in the prefrontal cortex (PMID: 19093364).
Immunomodulatory Properties Under Stress
Yasenyavskaya et al. (2021) published an important study in Current Reviews in Clinical and Experimental Pharmacology examining Selank’s influence on cytokine levels under social stress conditions. The research demonstrated that Selank reduced concentrations of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α as well as TGF-β1, practically restoring them to control values. These findings suggest Selank may possess stress-protective properties through immunomodulatory pathways (PMID: 32621722).
Dosage in Research Studies
Published research protocols vary considerably:
Note: These are research protocols only. Selank is a research chemical not approved for human use outside of controlled research settings.
Safety Profile in Research
Available safety data comes primarily from preclinical studies and limited clinical investigations:
The clinical trial by Zozulia et al. (2008) noted that Selank was generally well tolerated, with the peptide’s lack of direct benzodiazepine receptor binding contributing to a different side effect profile than traditional anxiolytics—specifically, an absence of the sedation, amnesia, and dependence concerns associated with benzodiazepines (PMID: 18454096).
The Vyunova et al. (2018) review also emphasized that Selank’s mechanism as a positive allosteric modulator of GABAA receptors, rather than a direct agonist, may contribute to its favorable safety profile in research contexts (PMID: 30255741). However, comprehensive long-term safety data remains limited and further investigation is needed.
Current Research Directions
Ongoing investigations are examining:
Related Research Peptides
Scientists investigating cognitive function and neuroprotection also study several related compounds:
Conclusion
Selank represents an interesting research tool for investigating anxiolytic mechanisms that differ from traditional GABAergic drugs. Current evidence from preclinical and limited clinical studies suggests potential effects on anxiety-like behaviors and cognitive function, mediated through multiple neurotransmitter systems and neurotrophic factors. The peptide’s unique position as a positive allosteric GABAA modulator with additional immunomodulatory properties makes it a compelling subject for continued laboratory investigation.
However, significant research gaps remain, particularly regarding long-term safety, optimal dosing protocols, and fully elucidating mechanisms of action. The peptide’s status as a research chemical means it lacks the comprehensive safety and efficacy data required for medical approval in most countries. All research with Selank should be conducted in accordance with applicable regulations and guidelines for research chemicals.
Future large-scale clinical trials with rigorous methodology will be essential to validate preliminary findings and establish whether Selank’s research promise translates to therapeutic applications.
Research References:
All research chemicals sold by Oath Research are intended for laboratory research use only. Not for human or animal consumption. Researchers must comply with all applicable regulations regarding the use of research chemicals.
Related Posts
semax: Stunning nootropic peptide for Best Focus
Curious about semax, nootropic peptide research? This article unpacks the science, mechanisms, and lab considerations behind the Russian-developed compound prized for its cognitive and neuroprotective promise.
Melanotan 2 Side Effects: What to Expect
Melanotan 2 (MT2) is a synthetic analog of alpha-melanocyte stimulating hormone that has gained attention in research settings for its effects on melanogenesis and melanocortin receptor pathways. While researchers explore its potential applications, understanding the complete side effect profile is essential for experimental safety protocols and informed study design. This comprehensive guide examines documented adverse …